Biologic agents in psoriasis
- 1 November 2006
- journal article
- review article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 47 (4), 217-230
- https://doi.org/10.1111/j.1440-0960.2006.00286.x
Abstract
This paper reviews the new biologic agents that selectively block the immunologic steps implicated in the pathogenesis of psoriasis. Four strategies have been targeted: reduction of the number of pathogenic T cells; inhibition of T-cell activation and migration; modulation of the immune system; and blockage of the activity of inflammatory cytokines. There are three classes: monoclonal antibodies, fusion proteins and recombinant cytokines or growth factors. The actions, efficacy and side-effect profile of the biologic agents, alefacept, efalizumab, etanercept and infliximab, are reviewed.Keywords
This publication has 67 references indexed in Scilit:
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasisJournal of the American Academy of Dermatology, 2004
- The efficacy and safety of etanercept in the re-treatment of psoriasis after relapseJournal of the American Academy of Dermatology, 2004
- Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment responseJournal of the American Academy of Dermatology, 2004
- Continuance on etanercept after early incomplete response in patients with psoriasisJournal of the American Academy of Dermatology, 2004
- The quality of life of patients with severe psoriasis treated with infliximabJournal of the American Academy of Dermatology, 2004
- CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyJournal of the American Academy of Dermatology, 2003
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000